Effect of conjugated linoleic acid, μ-calpain inhibitor, on pathogenesis of Alzheimer's disease

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1831, Issue 4, 2013, Pages 709-718

  Lee, Eunyoung ^a   Eom, Ji Eun ^a   Kim, Hye Lin ^a   Baek, Kyung Hye ^a   Jun, Kyu Yeon ^a   Kim, Hwa Jung ^a   Lee, Minyung ^a   Mook Jung, Inhee ^b   Kwon, Youngjoo ^a  

^a Ewha Womans University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Calpain inhibitor; A 1 42 oligomerization; Alzheimer's disease; Conjugated linoleic acid

Indexed keywords

CALPAIN; CONJUGATED LINOLEIC ACID; NEUROTOXIN; PROTEIN P25; PROTEIN P35; PROTEIN ZO1; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUROPROTECTION; OLIGOMERIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CALPAIN; CELL LINE, TUMOR; GLYCOPROTEINS; HUMANS; HYDROGEN PEROXIDE; LINOLEIC ACIDS, CONJUGATED; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84873440661     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2012.12.003     Document Type: Article

References (67)

1. K.A. Conway, E.W. Baxter, K.M. Fesenstein, and A.B. Reits Emerging beta-amyloid therapies for the treatment of Alzheimer's disease Curr. Pharm. Des. 9 2003 427 447
2. D.J. Selkoe The molecular pathology of Alzheimer's disease Neuron 6 1991 487 498
3. F. Checler Processing of the β-amyloid precursor protein and its regulation in Alzheimer's disease J. Neurochem. 65 1995 1431 1444
4. S. Yoon, and S. Ahn Jo Mechanisms of amyloid-β peptide clearance: potential therapeutic targets for Alzheimer's disease Biomol. Ther. 20 2012 245 255
5. K. Saito, J.S. Elce, J.E. Hamos, and R.A. Nixon Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration Proc. Natl. Acad. Sci. U. S. A. 90 1993 2628 2632
6. W.W. Smith, M. Gorospe, and J.W. Kusiak Signaling mechanisms underlying Abeta toxicity: potential therapeutic targets for Alzheimer's disease CNS Neurol. Disord. Drug Targets 5 2006 355 361
7. D.E. Goll, F.T. Valer, L. Hongqi, W. Wei, and C. Jinyang The calpain system Physiol. Rev. 83 2003 731 801
8. H.Y. Wu, K. Tomizawa, and H. Matsui Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder Acta Med. Okayama 51 2007 123 137
9. S.L. Chan, and M.P. Mattson Caspase and calpain substrate: roles in synaptic plasticity and cell death J. Neurosci. Res. 58 1999 167 190
10. K. Hyrc, S.D. Handran, S.M. Rothaman, and M.P. Goldberg Ionized intracellular calcium concentration predicts excitotoxic neuronal death: observations with low-affinity fluorescent calcium indicators J. Neurosci. 17 1997 6669 6677
11. M. Nikolic, H. Dudek, Y.T. Kwon, Y.F. Ramos, and L.H. Tsai The CDK5/p35 kinase is essential for neurite outgrowth during neuronal differentiation Genes Dev. 10 1996 816 825
12. M.S. Lee, Y.T. Kwon, M. Li, J. Peng, R.M. Friedlander, and L.H. Tsai Neurotoxicity induces cleavage of p35 to p25 by calpain Nature 405 2000 360 364
13. M. Hashiguchi, T. Saito, S. Hisanaga, and T. Hashiguchi Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau J. Biol. Chem. 277 2002 44525 44530
14. C. Gao, C. Hölscher, Y. Liu, and L. Li GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease Rev. Neurosci. 23 2011 1 11
15. X. Zhang, F. Li, A. Bulloj, Y.W. Zhang, G. Tong, Z. Zhang, F.-F. Liao, and H. Xu Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules FASEB J. 20 2006 1272 1274
16. H.W. Querfurth, and F.M. LaFerla Mechanisims of disease; Alzheimer's disease N. Engl. J. Med. 362 2010 329 344
17. K. Santacruz, J. Lewis, T. Spires, J. Paulson, L. Kotilinek, M. Ingelsson, A. Guimaraes, M. DeTure, M. Ramsden, E. McGowan, C. Forster, M. Yue, J. Orne, C. Janus, M. Kuskowski, B. Hyman, M. Hutton, and K.H. Ashe Tau suppression in a neurodegenerative mouse model improves memory function Science 209 2005 476 481
18. S. Oddo, V. Vasilevko, A. Caccamo, M. Kitazawa, D.H. Cribbs, and F.M. LaFerla Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles J. Biol. Chem. 281 2006 39413 39423
19. H.C. Tseng, Y. Zhou, Y. Shen, and L.H. Tsai A survey of CDK5 activator p35 and p25 levels in Alzheimer's disease brains FEBS Lett. 523 2002 58 62
20. J.C. Cruz, H.C. Tseng, J.A. Goldman, H. Shih, and L.H. Tsai Aberrant CDK5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles Neuron 30 2003 471 483
21. W. Nobel, V. Olm, K. Takata, E. Casey, O. Mary, J. Meyerson, K. Gaynor, J. LaFrancois, L. Wang, T. Kondo, P. Davis, M. Burns, Veeranna, R. Nixon, D. Dickson, Y. Matsuoka, M. Ahlijanian, L. Lau, and K. Duff CDK5 is a key factor in tau aggregation and tangle formation in vivo Neuron 38 2003 555 565
22. R. Siman, M. Baudry, and G. Lynch Brain fodrin: substrate for calpain I, an endogenous calcium-activated protease Proc. Natl. Acad. Sci. U. S. A. 81 1984 3572 3576
23. G.N. Patrick, L. Zukerberg, M. Nikolic, S. de la Monte, P. Dikkes, and L.H. Tsai Conversion of p35 to p25 deregulates CDK5 activity and promotes neurodegeneration Nature 402 1999 615 622
24. M. Higuchi, N. Iwata, Y. Matsuba, J. Takano, T. Suemoto, J. Maeda, B. Ji, M. Ono, M. Staufenbiel, T. Suhara, and T.C. Saido Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology FASEB J. 26 2012 1204 1217
25. G. Kusakawa, T. Saito, R. Onuki, K. Ishiguro, T. Kishimoto, and S. Hisanaga Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25 J. Biol. Chem. 275 2000 17166 17172
26. D.H. Kang, K.Y. Jun, J.P. Lee, C.S. Pak, Y. Na, and Y. Kwon Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity J. Med. Chem. 52 2009 3093 3097
27. A. Camins, E. Verdaguer, J. Folch, and M. Pallàs Involvement of calpain activation in neurodegenerative processes CNS Drug Rev. 12 2006 135 148
28. K.K. Wang, and P.W. Yuen Development and therapeutic potential of calpain inhibitors Adv. Pharmacol. 37 1997 117 152
29. E. Lee, J.E. Eom, H.L. Kim, D.H. Kang, K.Y. Jun, D.S. Jung, and Y. Kwon Neuroprotective effect of undecylenic acid extracted from Ricinus communis L. through inhibition of μ-calpain Eur. J. Pharm. Sci. 46 2012 17 25
30. D.L. Amaru, and C.J. Field Conjugated linoleic acid decreases MCF-7 human breast cancer cell growth and insulin-like growth factor-1 receptor levels Lipid 44 2009 449 458
31. L.D. Whingham, A.C. Watras, and D.A. Scholler Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans Am. J. Clin. Nutr. 85 2007 1203 1211
32. W.T. Hunt, A. Kamboi, H.D. Anderson, and C.M. Anderson Protection of cortical neurons from excitotoxicity by conjugated linoleic acid J. Neurochem. 115 2010 123 130
33. K.N. Dahlgren, A.M. Manelli, W.B. Stine Jr., L.K. Baker, G.A. Krafft, and M.J. LaDu Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability J. Biol. Chem. 277 2002 32046 32053
34. W. Fu, H. Luo, and S. Parthasarathy Catecholamines potentiate amyloid β-peptide neurotoxicity: involvement of oxidative stress, mitochondrial dysfunction, and perturbed calcium homeostasis Neurobiol. Dis. 5 1998 229 243
35. W. Kim, Y. Kim, J. Min, D.J. Kim, Y.T. Chang, and M.H. Hecht A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide Chem. Biol. 1 2006 461 469
36. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's β-amyloid fibrils in vitro Biochim. Biophys. Acta 1690 2004 193 202
37. Q. Li, R.P. Hanzlik, R.F. Weaver, and E. Schönbrunn Molecular mode of action of a covalently inhibiting peptidomimetic on the human calpain protease core Biochemistry 45 2006 701 708
38. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, and A.J. Olson Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function J. Comput. Chem. 19 1998 1639 1662
39. M.F. Sanner Python: a programming language for software integration and development J. Mol. Graph. Mod. 17 1998 57 61
40. M.W. Pariza Perspective on the safety and effectiveness of conjugated linoleic acid Am. J. Clin. Nutr. 79 2004 1132S 1136S
41. M.A. Belury Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action Annu. Rev. Nutr. 22 2002 505 531
42. W.L. Kllein Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets Neurochem. Int. 41 2002 345 352
43. C.C. Glabe Amyloid accumulation and pathogenesis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta Subcell. Biochem. 38 2005 167 177
44. A. Demuro, E. Mina, R. Kayed, S.C. Milton, I. Parker, and C.G. Glabe Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers J. Biol. Chem. 280 2005 17294 17300
45. N.A. Avdulov, S.V. Chochina, U. Igbavboa, E.O. O'Hare, F. Schroeder, J.P. Cleary, and W.G. Wood Amyloid beta-peptides increase annular and bulk fluidity and induce lipid peroxidation in brain synaptic plasma membranes J. Neurochem. 68 1997 2086 2091
46. S.D. Yan, X. Chen, J. Fu, M. Chen, H. Zhu, A. Roher, T. Slattery, L. Zhao, M. Nagashima, J. Morser, A. Migheli, P. Nawroth, D. Stern, and A.M. Schmidt RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease Nature 382 1996 685 691
47. M.S. Balda, and K. Matter The tight junction protein ZO-1 and an interacting transcription factor regulate ErbB-2 expression EMBO J. 19 2000 2024 2033
48. M.S. Balda, M.D. Garrett, and K. Matter The ZO-1-associated Y-box factor ZONAB regulates epithelial cell proliferation and cell density J. Cell Biol. 160 2003 423 432
49. H. Kazuma, S. Yoshihisa, S. Shuichi, and H. Toshiharu Zonula Occludens-1 alterations and enhanced intestinal permeability in methotrexate-treated rats Cancer Chemother. Pharmacol. 66 2010 1031 1038
50. 2 +-calcineurin signaling J. Neurosci. 32 2012 8845 8854
51. M. Tamai, C. Yokoo, M. Murata, K. Oguma, K. Sota, E. Sato, and Y. Kanaaoka Efficient synthetic method for ethyl (+)-(2S,3S)-3-[(S)-3-methyl-1-(3- methylbutylcarbamoyl)-2-oxiranecarboxylate (EST), a new inhibitor of cysteine proteases Chem. Pharm. Bull. 35 1987 1098 1104
52. E.B. McGowan, E. Becker, and T.C. Detwiler Inhibition of calpain in intact platelets by the thiol protease inhibitor E-64d Biochem. Biophys. Res. Commun. 158 1989 432 435
53. Z. Huang, E.B. McGowan, and T.C. Detwiler Ester and amide derivatives of E64c as inhibitors of platelet calpain J. Med. Chem. 35 1992 2048 2054
54. B. Liang, B.U. Duan, X.P. Zhou, J.X. Gong, and Z.G. Luo Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease J. Biol. Chem. 285 2010 27737 27744
55. F. Trinchese, M. Fa, S. Liu, H. Zhang, A. Hidalgo, S.D. Schmidt, H. Yamaguchi, N. Yoshii, P.M. Mathews, R.A. Nixon, and O. Arancio Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease J. Clin. Invest. 118 2008 2796 2807
56. M. Pallas, C. Knop, W. Behrens-Baumann, and C.K. Vorwerk Neuroprotective effects of calpain inhibitor MDL28170 in a model of intravitreal excitotoxicity Invest. Ophthalmol. Vis. Sci. 44 2003 110-B85
57. Y. Shirasaki, M. Nakamura, M. Yamaguchi, H. Miyashita, O. Sakai, and J. Inoue Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives J. Med. Chem. 49 2006 3926 3932
58. Y. Zeng, Q. Li, R.P. Hanzlik, and J. Aube Synthesis of a small library of diketopiperazines as potential inhibitors of calpain Bioorg. Med. Chem. Lett. 15 2005 3034 3038
59. Z. Li, A.C. Ortega-Vilian, G.S. Patil, D.L. Chu, J.E. Foreman, D.D. Eveleth, and J.C. Powers Novel peptidyl alpha-keto amide inhibitors of calpains and other cysteine proteases J. Med. Chem. 39 1996 4089 4098
60. A. Posner, K.J. Raser, I. Hajimohammadreza, P.W. Yuen, and K.K.W. Wang Aurintricarboxylic acid is an inhibitor of calpain I and II Biochem. Mol. Biol. Int. 36 1995 291 299
61. S. Omura, H. Tanaka, K. Shimoi, and J.R. Liu Pyrrole propionic acid amide (cystamidine A) manufacture with Streptomyces, and its use as calpain inhibitor Eur. Par. Appl. 1993 EP0569122A1
62. A. Kennedy, K. Martinez, S. Schmidt, S. Mandrup, K. LaPoint, and M. McIntosh Antiobesity mechanisms of action of conjugated linoleic acid J. Nutr. Biochem. 21 2010 171 179
63. M. Flowers, and P.A. Thompson t10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2 PLoS One 4 2009 e5342
64. U. Risérus, L. Berglund, and B. Vessby Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomized controlled trial Int. J. Obes. Relat. Metab. Disord. 25 2001 1129 1135
65. G.C. Burdge, B. Lupoli, J.J. Russell, S. Tricon, S. Kew, T. Banerjee, K.J. Shingfield, D.E. Beever, R.F. Grimble, C.M. Willians, P. Yaqoob, and P.C. Calder Incorporation of cis-9, trans-11 or trans-10, cis-12 conjugated linoleic acid into plasma and cellular lipids in health men J. Lipid Res. 45 2004 736 741
66. S. Garg, T. Timm, E.M. Mandelkow, E. Mandelkow, and Y. Wang Cleavage of tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment Neurobiol. Aging 32 2011 1 14
67. Y. Huang, and K.K.W. Wang The calpain family and human disease Trends Mol. Med. 7 2001 355 362